


Cite this: *RSC Adv.*, 2023, 13, 36200

Genome mining of actinomycin shunt products from *Kitasatospora* sp. YINM00002†

Zhou-Tian-Le Zhang,^{‡a} Hui-Bing Sun,^{‡a} Zhen Ren,^{‡b} Tian-Peng Xie,^a Ying-Fang Wang,^a Yin Guo,^a Xiaoyu Su,^a Min Yin,^{*a} Hao Zhou^{id}^{*a} and Zhong-Tao Ding^{id}^{ac}

Actinomycins are known for their anti-tumor, antibacterial and antiviral activities, and in particular for the ability of actinomycin D as a clinical drug to treat a variety of cancers. In our ongoing work to obtain novel natural products from endophytic actinomycetes derived from traditional Chinese herbs, we identified the potential to produce actinomycins in YINM00002, a *Kitasatospora* strain derived from *Polygonatum kingianum*. According to genome mining, we isolated actinomycins D and V (1 and 2) and small amounts of 4-methyl-3-hydroxyanthranilic acid (4-MHA) derivatives (3 and 4) from strain fermentation broth. The presence of actinrhater A (3) and actinrhater B (4) reveals a mysterious shunt pathway in the early stages of actinomycin D biosynthesis. Our study provides a fresh perspective for further discovery and modification of novel actinomycins.

Received 26th October 2023
Accepted 6th December 2023

DOI: 10.1039/d3ra07277k

rsc.li/rsc-advances

Introduction

Actinomycins have strong anti-tumor, antibacterial and antiviral activities, among which actinomycin D has been used in the clinical treatment of a variety of tumors, such as sarcomas, choriocarcinoma and lymphomas, especially for gestational trophoblastic neoplasia in women¹ and for pediatric tumors like Wilms tumor,² childhood rhabdomyosarcoma³ and Ewing's sarcoma.⁴ Actinomycin D could intercalate in the guanine-cytosine-rich regions of the transcription initiation complex, and prevent the elongation of the RNA chain. The strong dipole moment of actinomycin D, which might be provided by the phenoxazinone chromophore moiety, was thought to be the cause of the intercalation.^{5,6} In addition, the crystal structure of actinomycin D bound to a specific DNA sequence, ATGCGGCAT, has been resolved.⁷

Despite their strong biological activity, these compounds also have undesirable side-effects, limiting their clinical use.^{8,9} Therefore, it is necessary to investigate the biosynthetic

mechanisms of these compounds and obtain novel actinomycins with high activity and low toxicity through synthetic biological modifications. At present, several actinomycin biosynthetic gene clusters have been cloned from different *Streptomyces* strains, and parts of their biosynthetic mechanisms have been elucidated.^{10–14} To date, more than 40 analogues have been reported.^{15–22} The skeleton of actinomycins is composed of a phenoxazinone chromophore core, an α -peptidolactone and a β -peptidolactone. The biosynthesis of actinomycins is initiated by using tryptophan as starter, then five enzymes, including a tryptophan oxygenase, a kynurenine formamidase, a kynurenine 3-monooxygenase, a kynureninase and a hydroxykynureninase, converted tryptophan into the key building block 4-MHA.^{14,23–27} After that, the non-ribosomal peptide synthetases (NRPS) assembly line loaded five amino acids to the 4-MHA to form the pentapeptide precursor. However, the details of how the two MHA-pentapeptide monomers come together to generate the intact actinomycin are still unknown.

In order to find more active natural products, we focused on the endogenous and rhizospheric soil actinomycetes of traditional Chinese herbs. *Polygonatum kingianum* Coll. et Hemsl, a medicinal plant that can be used to treat osteoporosis, feebleness, and fatigue, is widely cultivated in Southwest China.²⁸ It is distinct in polysaccharides and possesses unique bioactivities, but the endogenous and rhizosphere actinomycetes live with it have not been studied. During the genome mining of the endophytic actinomycetes in this medicinal plant, we found that a strain of *Kitasatospora* possessed a putative actinomycin biosynthetic gene cluster that also demonstrated strong inhibitory activity against several pathogens. In

^aKey Laboratory of Functional Molecules Analysis and Biotransformation of Universities in Yunnan Province, Yunnan Characteristic Plant Extraction Laboratory, School of Chemical Science and Technology, School of Medicine, Yunnan University, University Town East Outer Ring South Road, Kunming, Yunnan 650500, China. E-mail: yinmin@ynu.edu.cn; haozhou@ynu.edu.cn

^bSchool of Agriculture and Life Sciences, Kunming University, 2 Pu Xin Road, Kunming, Yunnan 650214, China

^cCollege of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, 1076 Yu Hua Road, Kunming, Yunnan 650500, China

† Electronic supplementary information (ESI) available: 1D, 2D NMR and HRESIMS spectra of actinrhater A and B, along with other details. See DOI: <https://doi.org/10.1039/d3ra07277k>

‡ These authors contributed equally.



this study, we isolated actinomycins under the guidance of the genome mining study of strain YINM00002. In the meantime, we discovered two unexpected new compounds. The two compounds are the products of the amidation, glycosylation and cyclation of 4-MHA, a key building block in the actinomycin biosynthetic pathway. Based on these findings, we speculate that they are new shunt products in the actinomycin biosynthetic pathway.

Results and discussion

Taxonomy analysis of *Kitasatospora* sp. YINM00002

The neighbor-joining phylogenetic tree of the 16S rRNA gene sequences showed that strain YINM00002 formed a cluster with *Kitasatospora purpeofusca* LMG 20283^T (99.79% similarity)

(Fig. 1). The RAXML neighbor-joining phylogenomic tree demonstrated that YINM00002 formed a cluster with strain *Kitasatospora purpeofusca* NRRL ISP-5283^T under the 97 bootstrap values (Fig. 2), the maximum-likelihood tree and maximum-parsimony tree also showed it clustered with strain *Kitasatospora purpeofusca* NRRL ISP-5283^T under high bootstrap values (Fig. S1 and S2[†]). Phylogenetic analysis of strain YINM00002 indicates that it is a member of the genus *Kitasatospora*.

Antimicrobial activity and antibiotic resistance of *Kitasatospora* sp. YINM00002

Strains of *Kitasatospora* genus are capable of producing various types of antibiotics. *Kitasatospora* sp. YINM00002 has shown




Fig. 1 The neighbor-joining phylogenetic tree of strain YINM00002 and its closest relatives from the genus *Kitasatospora* based on 16S rRNA genes. Bootstrap values (>50%) based on 1000 resamplings are given at the nodes. *Streptacidiphilus albus* NBRC 100918T (accession no. BBPL01000138) was used as outgroup. Bar, 0.005 substitutions per nucleotide position.






Fig. 2 The RAxML neighbor-joining phylogenomic tree of strain YINM00002 and its closest relatives from the genus *Kitasatospora* based on marker genes. Bootstrap values (>70%) based on 100 resamplings are given at the nodes. *Streptacidiphilus albus* NBRC 100918^T (accession no. BBPL01000138) was used as outgroup. Bar, 0.02 substitutions per nucleotide position.

strong inhibitory activity against several pathogens, including *Escherichia coli*, *Staphylococcus aureus*, *Mycobacterium tuberculosis*, and *Bacillus subtilis*. At the same time, it could grow well on ISP2 medium with bacitracin. Antimicrobial activity and antibiotic resistance screening results indicate that *Kitasatospora* sp. YINM00002 may be a good strain for bioactive secondary metabolites discovery.

Genome mining of actinomycin gene cluster

With the assistance of a genome mining software antiSMASH 6.0, a gene cluster which might be responsible for actinomycin

biosynthesis was identified (Fig. 3). The putative gene cluster shows 89% similarity with the reported actinomycin gene cluster in a *Streptomyces chrysomallus* strain. Besides the start unit 4-MHA and the backbone non-ribosomal peptide (NRP) biosynthetic genes, additional genes, which coding regulators, oxidase, reductase, transporter and hypothetical proteins, are distributed on both sides of the entire gene cluster (Table 1). The high similarity of the core biosynthetic genes within the identified gene cluster and the reported actinomycin gene cluster showed strain YINM00002 is likely to produce actinomycins. Meanwhile, the inconsistency of the other genes




Fig. 3 The actinomycin biosynthetic gene cluster in YINM00002.



Table 1 Annotation of the main functional gene in the *acn* cluster

Identifier	Size ^a	Protein homolog and origin	ID/SM (%)	Origin (protein ID)
<i>Orf</i> (–1)	195	Hypothetical protein	73/100	WP_209415338.1 <i>Kitasatospora</i> sp. RG8
<i>acn</i> L	355	SCO0930 family lipoprotein	82/100	WP_230210278.1 <i>Streptomyces kaniharaensis</i>
<i>acn</i> F1	480	Ferredoxin	97/100	MBV2153232.1 <i>Kitasatospora</i> sp. SUK 42
<i>acn</i> U1	325	Hypothetical protein	84/100	WP_153464056.1 <i>Streptomyces kaniharaensis</i>
<i>acn</i> D1	464	DUF1996 domain-containing protein	91/100	WP_209415335.1 <i>Kitasatospora</i> sp. RG8
<i>acn</i> D2	244	DUF4142 domain-containing protein	88/100	WP_148648111.1 <i>Streptomyces</i> sp. CB01881
<i>acn</i> H	268	Helix-turn-helix domain-containing protein	89/91	WP_230210812.1 <i>Streptomyces kaniharaensis</i>
<i>acn</i> R1	309	LysR family transcriptional regulator	95/100	MBV6703076.1 <i>Kitasatospora aureofaciens</i>
<i>acn</i> C	856	Collagenase	76/100	WP_221503753.1 <i>Kitasatospora gansuensis</i>
<i>acn</i> R2	224	LuxR C-terminal-related transcriptional regulator	81/100	WP_188298505.1 <i>Streptomyces</i> sp. CBMA156
<i>acn</i> P2	1049	Cytochrome P450	83/98	WP_218198784.1 <i>Kitasatospora aureofaciens</i>
<i>acn</i> U2	210	Hypothetical protein	86/100	WP_051838397.1 <i>Streptomyces</i> sp. NRRL WC-3742
<i>acn</i> U3	186	Hypothetical protein	86/100	WP_057667199.1 <i>Streptomyces anulatus</i>
<i>acn</i> A6	66	MbtH family protein	97/100	WP_199823413.1 <i>Streptomyces</i> sp. NRRL WC-3742
<i>acn</i> A5	79	4-MHA carrier protein	69/98	WGD01484.1 <i>Streptomyces</i> sp.
<i>acn</i> A4	472	3-Hydroxy-4-methylanthranilate adenyltransferase AcmA	81/100	WP_078911522.1 <i>Streptomyces</i> sp. NRRL WC-3742
<i>acn</i> A1	2612	Non-ribosomal peptide synthetase	74/99	QIT48436.1 <i>Streptomyces antibioticus</i>
<i>acn</i> A2	2964	Non-ribosomal peptide synthetase	79/94	WP_104880054.1 <i>Streptomyces dengpaensis</i>
<i>acn</i> A3	1248	Non-ribosomal peptide synthetase	74/100	WP_078636602.1 <i>Streptomyces antibioticus</i>
<i>acn</i> U4	210	Hypothetical protein	93/100	WP_051838204.1 <i>Streptomyces</i> sp. NRRL WC-3742
<i>acn</i> B1	292	Arylformamidase	53/96	SBU91169.1 <i>Streptomyces</i> sp. Ncost-T6T-1
<i>acn</i> B2	281	Tryptophan 2,3-dioxygenase family protein	87/100	WP_031075029.1 <i>Streptomyces</i> sp. NRRL WC-3742
<i>acn</i> B3	420	Kynureninase	86/100	WP_096632687.1 <i>Streptomyces</i> sp. WZ.A104
<i>acn</i> B4	346	Methyltransferase	90/100	WP_275821042.1 <i>Streptomyces ferralitis</i>
<i>acn</i> P1	429	Cytochrome P450	84/96	WP_229893031.1 <i>Streptomyces xanthochromogenes</i>
<i>acn</i> F2	72	Ferredoxin	70/91	WP_161359452.1 <i>Streptomyces</i> sp. SID3343
<i>acn</i> R3	215	LmbU family transcriptional regulator	78/99	WP_248634514.1 <i>Streptomyces lichenis</i>
<i>acn</i> R4	257	TetR/AcrR family transcriptional regulator	74/98	WP_051781104.1 <i>Streptomyces antibioticus</i>
<i>acn</i> S	295	Siderophore-interacting protein	87/100	WP_031075040.1 <i>Streptomyces</i> sp. NRRL WC-3742
<i>acn</i> G1	326	ATP-binding cassette domain-containing protein	87/100	WP_255386436.1 <i>Streptomyces parvus</i>
<i>acn</i> T1	255	ABC transporter permease	96/100	WP_057667158.1 <i>Streptomyces anulatus</i>
<i>acn</i> T2	753	Excinuclease ABC subunit UvrA	89/100	WP_031075046.1 <i>Streptomyces</i> sp. NRRL WC-3742
<i>acn</i> R5	288	AfsR/SARP family transcriptional regulator	89/100	WP_238862110.1 <i>Kitasatospora</i> sp. A2-31
<i>acn</i> U5	174	Hypothetical protein	79/99	WP_238862109.1 <i>Kitasatospora</i> sp. A2-31
<i>acn</i> E	161	S26 family signal peptidase	87/96	WP_238862108.1 <i>Kitasatospora</i> sp. A2-31
<i>acn</i> G2	637	ABC transporter ATP-binding protein	92/95	MCG6495646.1 <i>Kitasatospora</i> sp. A2-31
<i>acn</i> U6	190	Hypothetical protein	85/100	WP_238862106.1 <i>Kitasatospora</i> sp. A2-31
<i>acn</i> U7	79	Hypothetical protein	96/100	WP_238862105.1 <i>Kitasatospora</i> sp. A2-31
<i>acn</i> Q	191	FAD binding domain-containing protein	90/96	WP_280701620.1 <i>Kitasatospora</i> sp. GP82
<i>acn</i> F3	1423	Bifunctional nitrate reductase	80/100	WP_280723810.1 <i>Kitasatospora</i> sp. MAA4
<i>acn</i> D3	356	DUF3048 domain-containing protein	83/100	WP_238862099.1 <i>Kitasatospora</i> sp. A2-31
<i>acn</i> R6	245	Crp/Fnr family transcriptional regulator	82/99	WP_117490432.1 <i>Kitasatospora xanthocidica</i>
<i>Orf</i> (–1)	284	Hypothetical protein	66/99	WP_074004766.1 <i>Streptomyces</i> sp. CB02056

^a Size in units of amino acids (aa).

between the two gene clusters indicated strain YINM00002 might have potential to generate novel members of actinomycin family (Fig. S3†).

Isolation of compounds guided by genome mining

As expected, red amorphous powder actinomycin D (1) and actinomycin V (2) were isolated from the 9# medium ferments of strain YINM00002. From the same crude extracts, two compounds (3 and 4) (Fig. 4) were found and elucidated as new products.

Compound 3 was obtained as faint yellow amorphous powder, the molecular formula of C₁₆H₂₁NO₈ was deduced from its HRESIMS at *m/z* 354.1193 [M – H][–] (calcd for C₁₆H₂₀NO₈,

354.1189) and ¹³C NMR data, indicating seven degrees of unsaturation. The ¹³C NMR data of 3 exhibited 16 carbons including two carbonyls (δ_{C} 170.6, 164.9), six aromatic carbons




Fig. 4 The structures of actinrhater A (3) and B (4).



Table 2 NMR data of actinrhater A (3) and B (4) in DMSO-*d*₆

No.	3 ^a				4 ^b			
	¹³ C, type	¹ H (J in Hz)	HMBC	COSY	¹³ C, type	¹ H (J in Hz)	HMBC	COSY
1	124.9, C	—	—	—	118.2, C	—	—	—
2	139.8, C	—	—	—	140.3, C	—	—	—
3	150.6, C	—	—	—	150.2, C	—	—	—
4	131.9, C	—	—	—	126.3, C	—	—	—
5	128.0, CH	7.12, d (7.9)	C-1,3	H-6	125.1, CH	7.30, d (7.9)	C-1,3,4	H-6
6	121.3, CH	7.21, d (8.0)	C-2,4,7	H-5	126.2, CH	7.80, d (7.9)	C-2,4,7	H-5
7	164.9, C	—	—	—	162.7, C	—	—	—
8	170.6, C	—	—	—	165.4, C	—	—	—
9	23.7, CH ₃	2.08, s	C-8	—	14.3, CH ₃	2.68, s	C-3,8	—
10	17.2, CH ₃	2.22, s	C-3,4,5	—	15.2, CH ₃	2.53, s	C-2,3,5,6	—
1'	95.2, CH	5.91, d (1.8)	C-7,5'	H-2'	94.5, CH	6.07, d (1.7)	C-7,5'	H-2'
2'	69.8, CH	3.75, m	—	H-1',3'	69.6, CH	3.80, m	C-4'	H-1',3'
3'	70.8, CH	3.53, m	—	H-2',4'	70.2, CH	3.83, m	—	H-2',4'
4'	72.0, CH	3.31, m	—	H-3',5'	71.6, CH	3.35, m	C-6'	H-3',5'
5'	71.7, CH	3.57, m	—	H-6',4'	71.2, CH	3.78, m	—	H-4',6'
6'	18.4, CH ₃	1.16, d (6.2)	C-3',4'	H-5'	17.9, CH ₃	1.17, d (6.2)	C-4'	H-5'
2'-OH		5.21, s				5.22, s		
3'-OH		4.75, s				4.76, d (6.0)		
4'-OH		4.97, s				4.95, d (5.3)		

^a 3 was measured at 400 MHz. ^b 4 was measured at 600 MHz.

(δ_C 121.3, 124.9, 128.0, 131.9, 139.8, 150.6), three methyls (δ_C 17.2, 18.4, 23.7), and five sugar-related methines (δ_C 69.8, 70.8, 71.7, 72.0, 95.2) (Table 2). Comparing the 1D and 2D NMR data of 3 to that of the known compound 2-acetylamin-3-hydroxyl-4-methyl-benzoic acid,²⁹ the aromatic moiety of 3 was determined. This was confirmed by HMBC correlations from H-5 to C-1 and C-3, from H-6 to C-2, C-4 and C-7, from H-10 to C-3, C-4 and C-5, from H-9 to C-8, together with COSY correlation between H-5 and H-6 (Fig. 5). In addition, the ¹H-¹H COSY correlations of H-1'/H-2'/H-3'/H-4'/H-5'/H₃-6' revealed the spin-system corresponding to the C-1' to C-6' unit in 3. Combined with the HMBC correlation from H-1' to C-5', the moiety of rhamnose was identified. Comparison of the 1D NMR data of the sugar moiety in compound 3 with those of rhamnose³⁰ also confirmed it. This was further verified by the hydrolysis experiment along with HRESIMS analysis of the sugar moiety (Fig. S28†). The specific rotation of the rhamnose moiety was [α]_D²⁵ −8.6 (c 0.1, MeOH) in accordance with that of authentic L-

rhamnose ([α]_D²⁵ −4.9 (c 0.1, MeOH)). The HMBC correlation from H-1' to C-7 indicated that the L-rhamnose moiety is connected to C-7 (Fig. 5). Thus, the structure of 3 was elucidated as a new benzoic acid glycosyl ester named as actinrhater A.

Actinrhater B (4) afforded a sodium adduct ion at *m/z* 360.1047 [*M* + Na]⁺ in agreement with a molecular formula of C₁₆H₁₉NO₇. The signal systems of the NMR of 4 resembled those of compound 3, suggesting structural similarity. The most evident difference was that one more degree of unsaturation was required than compound 3. Further aided by ¹H-¹H COSY and HMBC experiments (Fig. 5), the planar structure of 4 was established as dimethylbenzo[*d*]oxazole with the C-7 rhamnosyl ester as in 3, which was supported by the HMBC correlation from H-9 to C-3 and C-8. Moreover, the moiety of dimethylbenzo[*d*]oxazole in 4 was also confirmed by comparing with a recently reported literature.¹⁸ Then, the rhamnose moiety of 4 was determined to be the same L-rhamnose as that of 3 by its negative specific rotation. Accordingly, the structure of 4 was defined.




Fig. 5 ¹H-¹H COSY and key HMBC correlations of actinrhater A (3) and B (4).

Actinrhater are shunt products of actinomycin biosynthesis

4-MHA is the key starting unit for actinomycin chromophore formation, and a cluster including *acnB1*–*B4*, which encodes an arylformamidase, a tryptophan-2, a 3-dioxygenase, and a methyltransferase, has been identified in the middle of the putative actinomycin gene cluster in YINM00002, showing high similarity to known 4-MHA biosynthetic enzymes.

Previous *in vitro* studies have confirmed that the pathway of 4-MHA needed a tryptophan oxygenase, a kynurenine formamidase, a kynurenine 3-monooxygenase, a kynureninase and a hydroxykynureninase.^{14,23–27} Similar to the subcluster in an actinomycin producing strain of *Streptomyces costaricanus*




The presence of small amounts of compounds **3** and **4** reveals a mysterious shunt pathway in the early stages of actinomycin D biosynthesis. After the formation of 4-MHA, the main metabolites, catalyzed by the core enzymes described above, flow towards actinomycins biosynthesis, while a small amount of 4-MHA is converted to **3** by amidation and glycosylation, and then to **4** by cyclization. Whether the amidation, glycosylation and cyclization are catalyzed by enzymes or formed spontaneously remains to be discovered. No such enzymes were found in and around the *acn* gene cluster.

General experimental procedures

rotations were measured using a JASCO P-1020 digital polarimeter (Horiba, Tokyo, Japan). NMR spectra were recorded on a Bruker Avance-400 MHz instrument and a Bruker Avance-600 MHz instrument (Bruker, Karlsruhe, Germany) using tetramethylsilane as the internal standard. HRESIMS data were obtained by an Agilent 1200 Q-TOF mass instrument (Agilent, Santa Clara, CA, United States). The preparative HPLC was performed on an Agilent 1260 series equipped with a DAD detector and a Zorbax SB-C18 (250 × 9.4 mm, 5 mm) column. Sephadex LH-20 (GE Healthcare Bio-Science AB, Uppsala, Sweden), silica gel (200–300 mesh, Qingdao Marine Chemical Group Co., Qingdao, China) and Lichroprep RP-18 gel (40–63 mm, Merck, Darmstadt, Germany) were used for column chromatography (CC). Thinlayer chromatography (TLC) was performed on silica gel GF254 plates (Qingdao Haiyang Chemical Co., Ltd, Qingdao, China), which can be visualized by spraying with anisaldehyde–H₂SO₄ reagent. All solvents used were of analytical grade from Chengdu Titan Chron Chemical Co., Ltd (Chengdu, China).

Fresh rhizospheric soil samples of *Polygonatum kingianum* Coll. et Hemsl were randomly collected from the Chinese medicinal herb garden at Kunming University, Yunnan Province, China. All the samples were thoroughly mixed and then stored at 4 °C and processed within 12 h. Strain YINM00002 was isolated on M1 medium (asparagine 1 g, glycerol 10 g, K₂HPO₄·H₂O 1 g, MgSO₄·7H₂O 0.05 g, CaCO₃ 0.3 g, vitamin complex and trace



salt solution 1 mL, pH = 7.2) with nystatin and nalidixic acid (50 $\mu\text{g mL}^{-1}$ each), which had been inoculated with the soil sample suspension and incubated at 28 °C for up to a month. The isolate was picked out and purified three times on ISP2 plates with nystatin and nalidixic acid. The purified culture was preserved in ISP2 slants and 20% (v/v) glycerol tubes, stored at 4 °C and –80 °C respectively for further using. Genomic DNA isolation, 16S rRNA gene amplification and sequencing were performed as described previously.³¹

Antimicrobial activity and antibiotic resistance assay

Strain YINM00002 was inoculated on ISP2 agar disks and incubated at 28 °C for a week. The liquid cultures of activated pathogens, including *Escherichia coli* (CGMCC 1.2385), *Pseudomonas aeruginosa* (CGMCC 1.2387), *Bacillus subtilis* (CGMCC 1.1849), *Staphylococcus aureus* (CGMCC 1.2386), *Mycobacterium tuberculosis* (ATCC 25177), *Fusarium oxysporum* (MW149127.1), *Candida albicans* (CGMCC 2.2086) and *Fusarium fulcrum* (MW149128.1), were mixed well with Mueller–Hinton agar (beef extract powder 2 g, casein hydrolysate 17.5 g, starch 1.5 g, agar 12 g, pH = 7.3) 1:1 v/v, then spread on the top of ISP2 agar. Once the top agar had solidified, about 5 mm diameter ISP2 agar with a single colony of each isolated strains were placed on the top agar, incubated at 28 °C for a week.

Strain YINM00002 was inoculated on ISP2 agar supplemented with chloramphenicol (50 $\mu\text{g mL}^{-1}$), kanamycin (200 $\mu\text{g mL}^{-1}$), levofloxacin (50 $\mu\text{g mL}^{-1}$), vancomycin (50 $\mu\text{g mL}^{-1}$), rifampicin (50 $\mu\text{g mL}^{-1}$), oxytetracycline (50 $\mu\text{g mL}^{-1}$), apramycin (50 $\mu\text{g mL}^{-1}$), bacitracin (50 $\mu\text{g mL}^{-1}$), respectively, and incubated at 28 °C for 5 days.

Genome sequencing and actinomycin gene cluster identification

A single colony of strain YINM00002 was inoculated into 50 mL Tryptic Soy Broth (TSB) medium (casein tryptone 17 g, soy peptone 5 g, sodium chloride 5 g, D-glucose 2.5 g, dipotassium phosphate 2.5 g, H₂O up to 1000 mL, pH = 7.3) for 36 h at 28 °C with 200 rpm vigorous shaking. Next the strain was stored with dry ice and sent to Majorbio (Shanghai, China) for complete genome sequencing. After sequencing by Pacbio and Illumina Hiseq Technologies, the biosynthetic gene cluster of actinomycin was identified using the antiSMASH 6.0,³² and then verified by manual inspection.

Fermentation of strain YINM00002

For small-scale fermentation, the strain YINM00002 was activated in ISP2 medium at 28 °C for a week. The activated strain was inoculated into 500 mL Erlenmeyer flasks containing 100 mL of ISP2 medium and cultured for 2 days at 28 °C and 200 rpm. Then, 1.0 mL of the seed culture was transferred into 500 mL Erlenmeyer flasks containing 100 mL of 5 different types of fermentation media (2#, 3#, 9#, 10# and 15#, data not show), respectively. The crude extracts of 5, 10, 15 days ferments were detected with high performance liquid chromatograph (HPLC) and thin layer chromatography (TLC) to determine the optimal fermentation condition.

For large-scale fermentation, seed cultures of strain YINM00002 were prepared as described above. Then, 1.0 mL of the seed cultures were transferred into 500 mL Erlenmeyer flasks containing 100 mL of 9# fermentation media (glucose 10 g, glycerol 10 mL, corn extract 2.5 g, peptone 5 g, soluble starch 10 g, yeast extract 2 g, calcium carbonate 3 g, sodium chloride 1 g, H₂O up to 1000 mL, pH = 7.3), and cultured for 10 days at 28 °C and 200 rpm (13.5 L).

Isolation and identification of compounds

The fermentation broth of strain YINM00002 (13.5 L) was extracted with equal volume ethyl acetate three times to afford an EtOAc extract (10.5 g). The crude extract was separated into five fractions (Fr.1–Fr.5) by a silica gel column with a petroleum ether–acetone gradient system (1:0, 30:1, 10:1, 5:1, 0:1). Fr.2 was fractionated using a Sephadex LH-20 column with MeOH to obtain Fr.2-1 to Fr.2-3. Fr.2-2 was fractionated by LiChroprep RP-18 column, and eluted stepwise with a MeOH–H₂O gradient (40% MeOH, 60% MeOH, 80% MeOH and 100% MeOH) to afford Fr.2-2-1 to Fr.2-2-4. Fr.2-2-3 was separated by HPLC using a Zorbax SB-C18 column (250 × 9.4 mm, 5 μm ; the mobile phase is 95% MeOH; the flow rate is 3.0 mL min^{–1}; detection wavelength 440 nm) to give compounds **1** (20.7 mg, t_{R} = 28.5 min) and **2** (13.2 mg, t_{R} = 27.5 min). Fr.3 was divided into four parts (Fr.3-1 to Fr.3-4) by a Sephadex LH-20 column with MeOH. Compounds **3** (4.5 mg, t_{R} = 10.0 min) and **4** (3.4 mg, t_{R} = 14.8 min) were obtained from Fr.3-4 by HPLC purification. (Zorbax SB-C18 column: 250 × 9.4 mm, 5 μm ; the mobile phase 55% MeOH; the flow rate 3.0 mL min^{–1}; detection wavelength 300 nm).

Actinrhater A (3). Faint yellow amorphous powder; $[\alpha]_{\text{D}}^{25}$ –8.6 (c 0.1, MeOH); λ_{max} (log ϵ) 220.0 (2.34), 304.0 (2.48); ¹H and ¹³C NMR data, Table 2; HRESIMS m/z 354.1193 [M – H][–] (calcd for C₁₆H₂₀NO₈, 354.1194).

Actinrhater B (4). White amorphous powder; $[\alpha]_{\text{D}}^{25}$ –6.9 (c 0.1, MeOH); λ_{max} (log ϵ) 214.0 (2.33), 256.0 (2.40), 288.0 (2.45); ¹H and ¹³C NMR data, Table 2; HRESIMS m/z 360.1047 [M + Na]⁺ (calcd for C₁₆H₁₉NO₇Na, 360.1054).

Identification of the sugar moiety

Compounds **3** and **4** were hydrolyzed using 5% HCl (10 mL) at 60 °C for 6 h, respectively. Both dissociated sugar moieties were obtained and characterized by HRESIMS (m/z 163.0611 and 163.0608 [M – H][–], calcd for C₆H₁₁O₅, 163.0612). The identification of L-rhamnose was then carried out by comparison of their specific rotations with that of an authentic sample under the same conditions. The specific rotation of rhamnose moieties from **3** and **4** were $[\alpha]_{\text{D}}^{25}$ –8.6 (c 0.1, MeOH) and $[\alpha]_{\text{D}}^{25}$ –6.9 (c 0.1, MeOH) respectively, in accordance with that of L-rhamnose, which was $[\alpha]_{\text{D}}^{25}$ –4.9 (c 0.1, MeOH).³³

Conclusions

In this study, we identified a putative actinomycin biosynthetic gene cluster in *Kitasatospora* sp. YINM00002 through genome mining, and also found small amounts of two new compounds



actinrhater A (3) and B (4). The 4-MHA, a key node in the biosynthetic flow of actinomycins under NRPS catalysis, is also converted into actinrhater A and B by amidation, glycosylation and cyclization. The discovery of a branch of actinomycin biosynthesis provides a fresh perspective for further discovery and modification of novel actinomycins.

Data availability

This strain had been deposited at the Yunnan University under accession number YINM00002. The sequence of the actinomycin biosynthetic gene cluster in strain YINM00002 was deposited in GenBank under accession number OR217453.

Author contributions

M. Y., H. Z. and Z. D. designed the study, carried out the data analysis and wrote the manuscript. Z. Z., H. S., and Z. R. carried out the experiments and participated in data analysis. T. X., Y. W., Y. G., X. S. participated in data analysis, all authors have read and approved the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This research was financially supported by the National Natural Science Foundation of China (82160674 and 31860017 for M. Y., 22267001 for Z. D.), Yunnan Revitalization Talent Support Program (YNWR-QNBJ-2019-031 for M. Y., YNWR-QNBJ-2020-096 for Z. R.), Natural Science Foundation of Yunnan Province (202201AS070007, 202001BB050069 and 202002AA100007 for M. Y., 202201AT070225 for H. Z. and 202101BA070001-035 for Z. R.), Yunnan Key Laboratory of Stomatology, The Affiliated Stomatology Hospital of Kunming Medical University (2022YNKQ005 for M. Y.) and Yunnan University Graduate Research Innovation Fund.

References

- 1 D. P. Goldstein and R. S. Berkowitz, *Hematol./Oncol. Clin. North Am.*, 2012, **26**, 111–131.
- 2 M. Malogolowkin, C. A. Cotton, D. M. Green, N. E. Breslow, E. Perlman, J. Miser, M. L. Ritchey, P. R. M. Thomas, P. E. Grundy, G. J. D'Angio, J. B. Beckwith, R. C. Shamberger, G. M. Haase, M. Donaldson, R. Weetman, M. J. Coppes, P. Shearer, P. Coccia, M. Kletzel, R. Macklis, G. Tomlinson, V. Huff, R. Newbury and D. Weeks, *Pediatr. Blood Cancer*, 2008, **50**, 236–241.
- 3 S. X. Skapek, A. Ferrari, A. A. Gupta, P. J. Lupo, E. Butler, J. Shipley, F. G. Barr and D. S. Hawkins, *Nature Reviews Disease Primers*, 2019, **5**, 1.
- 4 N. Jaffe, D. Traggis, S. Salian and J. R. Cassady, *Cancer*, 1976, **38**, 1925–1930.
- 5 J. Gallego, A. R. Ortiz, B. dePascualTeresa and F. Gago, *J. Comput.-Aided Mol. Des.*, 1997, **11**, 114–128.
- 6 N. R. Bachur, M. V. Gee and S. L. Gordon, *Proceedings of the American Association for Cancer Research*, 1978, **19**, 75–83.
- 7 Y. S. Lo, W. H. Tseng, C. Y. Chuang and M. H. Hou, *Nucleic Acids Res.*, 2013, **41**, 4284–4294.
- 8 B. Langholz, J. M. Skolnik, J. S. Barrett, J. Renbarger, N. L. Seibel, A. Zajicek and C. A. S. Arndt, *Pediatr. Blood Cancer*, 2011, **57**, 252–257.
- 9 R. J. Osborne, V. Filiaci, J. C. Schink, R. S. Mannel, A. A. Secord, J. L. Kelley, D. Provencher, D. S. Miller and A. L. Covens, *J. Clin. Oncol.*, 2011, **29**, 825–831.
- 10 F. Pfennig, F. Schauwecker and U. Keller, *J. Biol. Chem.*, 1999, **274**, 12508–12516.
- 11 F. Fawaz and G. H. Jones, *J. Biol. Chem.*, 1988, **263**, 4602–4606.
- 12 M. C. Liu, Y. X. Jia, Y. C. Xie, C. Y. Zhang, J. Y. Ma, C. L. Sun and J. H. Ju, *Mar. Drugs*, 2019, **17**, 240.
- 13 U. Keller, M. Lang, I. Crnovcic, F. Pfennig and F. Schauwecker, *J. Bacteriol.*, 2010, **192**, 2583–2595.
- 14 I. Crnovcic, C. Ruckert, S. Semsary, M. Lang, J. Kalinowski and U. Keller, *Adv. Appl. Bioinf. Chem.*, 2017, **10**, 29–46.
- 15 J. Bitzer, V. Gesheva and A. Zeeck, *J. Nat. Prod.*, 2006, **69**, 1153–1157.
- 16 W. L. Cai, X. C. Wang, S. I. Elshahawi, L. V. Ponomareva, X. D. Liu, M. R. McErlean, Z. Cui, A. L. Arlinghaus and J. S. Thorson, *J. Nat. Prod.*, 2016, **79**, 2731–2739.
- 17 N. V. Machushynets, S. S. Elsayed, C. Du, M. A. Siegler, M. de la Cruz, O. Genilloud, T. Hankemeier and G. P. van Wezel, *Sci. Rep.*, 2022, **12**, 2813.
- 18 W. Z. Zhao, G. F. Wang, L. Guo, J. M. Wang, C. C. Jing, B. Liu, F. Zhao, S. M. Zhang and Z. P. Xie, *Org. Biomol. Chem.*, 2023, **21**, 1737–1743.
- 19 Q. Wang, Y. Zhang, M. Wang, Y. Tian, X. X. Hu, H. W. He, C. L. Xiao, X. F. You, Y. G. Wang and M. L. Gan, *Sci. Rep.*, 2017, **7**, 3591.
- 20 Y. Q. Chen, J. J. Liu, B. Yuan, C. L. Cao, S. Qin, X. Y. Cao, G. K. Bian, Z. Wang and J. H. Jiang, *Mol. Carcinog.*, 2013, **52**, 983–996.
- 21 W. H. Jiao, W. Yuan, Z. Y. Li, J. Li, L. Li, J. B. Sun, Y. H. Gui, J. Wang, B. P. Ye and H. W. Lin, *Tetrahedron*, 2018, **74**, 5914–5919.
- 22 M. Dong, P. Cao, Y. T. Ma, J. Y. Luo, Y. J. Yan, R. T. Li and S. X. Huang, *Nat. Prod. Res.*, 2019, **33**, 219–225.
- 23 D. D. Brown, M. J. M. Hitchcock and E. Katz, *Arch. Biochem. Biophys.*, 1980, **202**, 18–22.
- 24 D. Brown, M. J. M. Hitchcock and E. Katz, *Can. J. Microbiol.*, 1986, **32**, 465–472.
- 25 J. W. Foster and E. Katz, *J. Bacteriol.*, 1981, **148**, 670–677.
- 26 A. Haese and U. Keller, *J. Bacteriol.*, 1988, **170**, 1360–1368.
- 27 T. Troost, M. J. M. Hitchcock and E. Katz, *Biochim. Biophys.*, 1980, **612**, 97–106.
- 28 R. S. Li, A. E. Tao, R. M. Yang, M. Fan, X. C. Zhang, Z. F. Du, F. N. Shang, C. L. Xia and B. Z. Duan, *Biomed. Pharmacother.*, 2020, **131**, 110687.
- 29 X. F. Zhang, X. W. Ye, W. Y. Chai, X. Y. Lian and Z. Z. Zhang, *Mar. Drugs*, 2016, **14**, 181.



- 30 L. Lartigue, K. Oumzil, Y. Guari, J. Larionova, C. Guérin, J. L. Montero, V. Barragan-Montero, C. Sangregorio, A. Caneschi, A. C. Innocenti, T. Kalaivani, P. Arosio and A. Lascialfari, *Org. Lett.*, 2009, **11**, 2993–2995.
- 31 R. Li, M. Wang, Z. Ren, Y. Ji, M. Yin, H. Zhou and S. K. Tang, *Front. Microbiol.*, 2021, **12**, 743116.
- 32 K. Blin, S. Shaw, A. M. Kloosterman, Z. Charlop-Powers, G. P. van Wezel, M. H. Medema and T. Weber, *Nucleic Acids Res.*, 2021, **49**, W12–W35.
- 33 M. Jiang, Y. Zhang, Y. X. Zhang, Z. J. Ma and J. H. Wang, *J. Nat. Prod.*, 2022, **85**, 1771–1778.

